Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and related share sale. On February 9, 2026, he exercised 4,991 ResMed common stock options at an exercise price of
That same day, he sold 4,991 ResMed common shares in market transactions at a weighted average price of
ResMed (RMD) insider Michael Farrell has filed to sell common shares under Rule 144. The notice covers 4,991 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of
The 4,991 shares were acquired on
By signing the notice, the seller represents that he does not know of any undisclosed material adverse information about ResMed’s current or prospective operations.
ResMed Inc. director Peter C. Farrell, who serves as chairman emeritus, reported selling 2,000 shares of ResMed common stock on February 4, 2026 at a price of $251.31 per share. After this transaction, he beneficially owned 64,773 shares directly. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan that was adopted on August 12, 2025, indicating the trade followed an advance, systematic plan rather than a discretionary same‑day decision.
ResMed Inc.'s Global General Counsel Michael J. Rider reported a small automatic share sale under a pre-set trading plan. On 02/04/2026, he sold 50 shares of ResMed common stock at $260 per share in a transaction coded as a sale.
After this trade, he beneficially owned 9,691 shares, all reported as directly held. The filing notes that the transaction was conducted under a Rule 10b5-1 plan adopted on February 28, 2025, indicating it was pre-arranged rather than a discretionary market-timed trade.
A shareholder, Peter C Farrell, has filed a notice of intent to sell 2,000 shares of common stock through Merrill Lynch on the NYSE. The planned sale has an aggregate market value of 502540, with 44,448,959 shares of the issuer’s stock reported as outstanding and an approximate sale date of 02/04/2026.
The 2,000 shares were acquired on 11/11/2014 via a stock option transaction for cash. Over the prior three months, Peter C Farrell sold 2,000 shares on each of three dates, with gross proceeds of 504020, 502860, and 497580, indicating a pattern of periodic share sales.
A shareholder in RMD filed a Form 144 notice to sell 50 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of
ResMed Inc.’s Chief Financial Officer Brett Sandercock reported a planned sale of company stock. On February 2, 2026, he sold 1,000 shares of ResMed common stock at $257.03 per share under a Rule 10b5-1 trading plan adopted on February 19, 2025.
After this transaction, Sandercock directly holds 85,495 ResMed shares. Rule 10b5-1 plans allow executives to pre-schedule trades, helping separate routine portfolio moves from day-to-day market or company news.
Brett Sandercock filed a notice of proposed sale of 1,000 shares of common stock with an aggregate market value of 257,030.00, to be sold through Fidelity Brokerage Services LLC on the NYSE around 02/02/2026.
The 1,000 shares were acquired on 11/11/2022 through restricted stock vesting from the issuer as compensation. Over the prior three months, Brett Sandercock sold 3,000 common shares on 11/03/2025 for gross proceeds of 742,620.00, 1,000 shares on 12/01/2025 for 244,160.00, and 1,000 shares on 01/02/2026 for 241,750.00.
ResMed Inc. reported solid quarterly growth, with net revenue for the three months ended December 31, 2025 rising to $1.42 billion, up 11% from a year earlier (9% in constant currency). Sleep and Breathing Health products drove most of the increase, with devices and masks both seeing higher demand and unit sales across the U.S., Canada, Latin America, Europe, Asia and other markets.
Residential Care Software revenue grew 7% to $166.9 million, helped by strength in the MEDIFOX DAN and Home and Hospice verticals, partly offset by softer Senior Living and Long-Term Care performance. Company-wide gross margin improved to 61.8% from 58.6%, mainly due to manufacturing and logistics efficiencies and lower component costs.
Net income for the quarter grew to $392.6 million, with diluted earnings per share increasing to $2.68 from $2.34. For the first six months of the fiscal year, revenue reached $2.76 billion, up 10%, and gross margin rose to 61.6%. ResMed ended the period with $1.42 billion in cash and cash equivalents and $6.32 billion in stockholders’ equity, providing a sizable financial cushion alongside its global growth initiatives.
ResMed Inc. filed a current report describing its latest quarterly results and a new dividend declaration. The company issued a press release covering operations for the quarter ended December 31, 2025, which is furnished as an exhibit and not treated as filed for liability purposes.
ResMed’s board declared a quarterly cash dividend of US $0.60 per share, with a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. dollars to NYSE common stockholders. Holders of CHESS Depositary Instruments on the ASX will receive the equivalent in Australian dollars based on the exchange rate on the record date, reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date is February 11, 2026 for both common stock and CDIs, and ResMed obtained an ASX waiver to defer conversions between its common stock and CDI registers from February 11–12, 2026.